AstraZeneca said on Friday that profit after tax rose 23% to $3.12bn for the July to September period, driven largely by its cancer treatments, according to reporting by Euronews (euronews.com). Alongside the results, the London-listed group launched a restructuring programme intended to generate $1.5bn in annual savings, which it plans to reinvest mainly in drugs still in development.
The quarter marks a sharp pick-up from growth of just over 2% in the previous three months, Euronews reported. Oncology, AstraZeneca's largest business, accounted for 48% of the total, with sales up 17% to $7.8bn, led by the lung cancer drug Tagrisso and the immunotherapy Imfinzi. Core earnings per share, which strip out items such as restructuring costs and the amortisation of acquired drugs, rose 17% to $2.79.
A savings plan with a price tag
The programme, called Reshaping for Sustainable Growth, will cost up to $2bn in one-off restructuring charges and is due to be largely complete by the end of 2029, according to Euronews. The Evening Standard (standard.co.uk) reported the same figures in sterling, describing a three-year overhaul to cut costs by $1.5bn, or £1.1bn, a year, with restructuring charges of up to $2bn, or £1.5bn. The company said the savings would be redeployed across its existing business and therapy areas to back more than 180 projects in development. Euronews reported that such restructuring could mean job cuts, though none have been announced. The Evening Standard reported that AstraZeneca declined to provide details on where the savings would come from and whether jobs would be affected. Chief financial officer Aradhana Sarin gave the clearest indication of direction, telling the Evening Standard that the programme would involve hiring more in some areas and cutting back in others. "Overall we do expect that the company will continue to grow, we are not expecting to shrink the headcount," she said. She described a reshaping exercise in which some employees are upskilled or reskilled and new skills and technology areas are brought in, while other areas are reduced or reorganised slightly. She said the programme would be "widespread" and therefore not targeted at one specific location or business unit.What the quarter shows beneath the headline
The growth came despite pressure on older medicines. Sales of Farxiga, used to treat diabetes, heart and kidney disease, fell 25% to $1.6bn after cheaper generic versions reached the US market, while the blood thinner Brilinta also lost patent protection, Euronews reported. AstraZeneca is additionally facing volume-based procurement in China, a state bulk-buying scheme that forces drugmakers to cut prices in exchange for large orders. The Evening Standard reported that pre-tax profits jumped 22% to $3.96bn, or £2.9bn, and operating profits rose 22% to $4.39bn, or £3.21bn, both ahead of expectations. Shares rose by around 6% on Friday to about £138, their highest since July, according to the Evening Standard; Euronews put the early-session gain at more than 4.5%.The pipeline behind the cost cuts
AstraZeneca confirmed its outlook for 2026, expecting revenue to grow by a mid-to-high single-digit percentage and core earnings per share by a low double-digit percentage, excluding currency swings, Euronews reported. It remains on track for a target of $80bn in annual revenue by 2030, against almost $59bn in 2025, with half of that expected to come from the US. The Evening Standard reported that the company expects about 20 new medicine launches to underpin the target. Chief executive Pascal Soriot said: "With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade." The same passage was reported by both Euronews and the Evening Standard. AstraZeneca has been leaning further into the American market, adding a direct share listing in New York in February, while pledging to invest $15bn in China by 2030, according to Euronews. It has reported 12 positive results from late-stage trials so far this year and is developing a weight-loss treatment to compete with Novo Nordisk's Wegovy and Eli Lilly's Mounjaro. The Evening Standard put global employment at 100,000, of whom around 10,000 are based in the UK. Its global headquarters are in Cambridge, with UK research and development and manufacturing sites in Macclesfield, Cheshire, as well as sites in London and Speke, Liverpool.Why It Matters
The results show a large pharmaceutical group using growth from its most productive franchise to pay for a reshaping of the wider business, rather than simply banking the gain. Oncology is carrying the group, but the drag from generic competition on Farxiga and Brilinta, and the pricing pressure of China's bulk-buying scheme, illustrate how quickly older revenue can erode. The savings programme is best read as a reallocation of capacity towards the pipeline rather than a retreat: the company is funding more than 180 development projects and expects roughly 20 new launches to support its 2030 revenue target. For operators in capital-intensive sectors, the structure is instructive. AstraZeneca has attached a defined cost to the savings, up to $2bn in charges, and a timetable, largely complete by the end of 2029. It has also declined to specify where the reductions fall, which leaves the workforce and site-level implications unresolved even as the financial logic is set out.Commercial Impact
The immediate commercial effect is a stronger share price and a reaffirmed outlook, with the market rewarding a quarter that beat expectations. The medium-term effect depends on whether the reinvested savings convert into late-stage trial successes and launches. AstraZeneca's exposure to US pricing and to China's procurement regime means the savings programme buys flexibility as much as it improves margins. Suppliers and partners across its UK sites in Cambridge, Macclesfield, London and Speke will be watching for indications of where resources are redeployed, though the company has said the programme is not targeted at a single location or unit.Risks and Unknowns
Several elements remain unclear. Neither report specifies where the savings will come from, and no job cuts have been announced. The restructuring charges of up to $2bn are a range, not a fixed figure, and the 2029 completion date is described as largely, not fully, complete. The 2026 guidance and the 2030 revenue target are forward-looking and exclude currency swings. The weight-loss programme is at development stage and competes with established treatments from Novo Nordisk and Eli Lilly; no timeline for it was given in the sources.FY Outlook
The next signals to watch are the detail of where the reshaping falls and whether headcount guidance holds as the programme progresses. AstraZeneca has said it does not expect to shrink overall headcount, which sets a benchmark against which subsequent disclosures can be judged. The company's ability to keep oncology growing fast enough to offset generic erosion elsewhere, and to convert its late-stage trial results into launches, will determine whether the savings are a margin cushion or a genuine shift in investment capacity.Sources and References
- Euronews — euronews.com
- Evening Standard — standard.co.uk
